X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nomacopan
Therapeutic Area: Dermatology Product Name: rVA576
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 28, 2021
Details:
Nomacopan has potential to replace long term steroid treatment (standard of care) in BP, which has multiple adverse effects and increases mortality in this elderly and frail population.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Nomacopan
Therapeutic Area: Dermatology Product Name: rVA576
Highest Development Status: Phase III Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2021
Details:
Akari Therapeutics have opened an investigational new drug application (IND) with the FDA for its multicentre Phase III study with nomacopan, for the treatment of moderate and severe bullous pemphigoid (BP).
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
